ADSCC general manager Dr Yendry Ventura. Credit: The PR Acaddemy MENA on behalf of Abu Dhabi Stem Cells Center (ADSCC) / PRNewswire.

Abu Dhabi Stem Cells Center (ADSCC) has announced plans to commence a Phase I/II clinical study of Extracorporeal Photopheresis (ECP) technology to treat multiple sclerosis.

The new technology provides immunomodulatory effects and has been used in the treatment of advanced cutaneous T-cell lymphoma (CTCL) skin symptoms.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It has also been used to fight conditions that share some of the characteristics of multiple sclerosis.

The ADSCC will recruit 45 subjects for the clinical trial, which has been designed to assess the efficacy and safety of the ECP technology.

The Research Committee of the Department of Health, Abu Dhabi, has already granted approval for the study.

See Also:

The company stated that the Phase I/II clinical study has the potential to revolutionise global care for patients with debilitating illnesses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADSCC general manager and immunology specialist Dr Yendry Ventura said: “The UAE is introducing unique and innovative treatments to the region in this groundbreaking clinical trial.

“Multiple sclerosis is a debilitating disease with a devastating impact on many patients’ lives in the Middle East and around the world; our world-leading research centre has the chance to advance global biotechnology treatments to the next level.

“Researchers will closely evaluate 45 patients during the one-year trial, and we anticipate providing life-changing remedies for people in the UAE, the Middle East and beyond.”

Founded in March 2019, the company aims to meet the increasing domestic and regional demands for advanced medical services, as well as innovative treatments in the UAE.

Recently, it has succeeded in its first trial to manufacture CAR T-cells locally in a laboratory.

The ADSCC will also begin clinical trials to evaluate the CAR T-cell therapy’s effectiveness and safety for the treatment of hematologic cancers.

Furthermore, the stem cell research hub is working to create treatments for type-1 diabetes.